Apremilast(Amgen)은 Psoriatic Arthritis 표적 치료제로, Psoriasis; Atopic Dermatitis 영역에서 개발·상용화 중입니다. 작용기전: target modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling. FDA 승인 또는 승인 단계 프로그램입니다. The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.. PK: t½ 9 h. 차별점: novel indications-offers a cost-effective strategy to accelerate the development of alternative therapies with established sa.
Psoriatic Arthritis
Psoriasis; Atopic Dermatitis
Active
novel indications-offers a cost-effective strategy to accelerate the development of alternative therapies with established sa
target modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling
immune-mediated skin disorder characterized by excessive inflammation and the overexpression of pro-inflammatory cytokines, including I
downregulation of BACH1
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Apremilast(Amgen)은 Psoriatic Arthritis 표적 치료제로, Psoriasis; Atopic Dermatitis 영역에서 개발·상용화 중입니다. 작용기전: target modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling. FDA 승인 또는 승인 단계 프로그램입니다. The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.. PK: t½ 9 h. 차별점: novel indications-offers a cost-effective strategy to accelerate the development of alternative therapies with established sa.
Psoriatic Arthritis
Psoriasis; Atopic Dermatitis
Active
novel indications-offers a cost-effective strategy to accelerate the development of alternative therapies with established sa
target modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling
immune-mediated skin disorder characterized by excessive inflammation and the overexpression of pro-inflammatory cytokines, including I
downregulation of BACH1
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.